Human Reproduction, Vol. 16, No. 4, 632-637,
April 2001
© 2001 European Society of Human Reproduction and Embryology
Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations
1 Department of Obstetrics and Gynecology, Rabin Medical Center, Petah Tigva, Israel, 2 Department of Obstetrics and Gynecology, Hadassah Medical Center, Jerusalem, Israel, 3 Centre for Reproduction, Growth and Development, University of Leeds, UK and 4 Women's Pavilion, Royal Victoria Hospital, Montreal, Canada
This study assessed reproductive performance, fetal viability and teratogenicity in female mice exposed to cyclophosphamide across a timeline corresponding to different stages of follicle maturation. Pregnancies were established in female Balb/c mice 1–4 weeks after administration of a non-sterilizing dose of cyclophosphamide (75 mg/kg). Each mating group represented a different stage of follicular growth at the time of cyclophosphamide exposure. The number of corpora lutea, pregnancies and fetal resorptions were determined. Surviving fetuses were evaluated for gross malformations. Results indicated that conceptions attributable to follicles exposed to cyclophosphamide at a mature stage had a significantly lower number of implantation sites, 4.82 ± 1.01 versus 8.27 ± 0.81 in controls (P = 0.001) and a high resorption rate, 56% ± 0.11 versus 34% ± 0.07 in controls (P = 0.05). The proportion of corpora lutea in this group which resulted in viable fetuses was extremely low, 0.2 ± 0.06 versus 0.51 ± 0.07 in controls (P = 0.001). Malformation rate was more than 10 times higher in all treated groups (P < 0.05) and a particularly high incidence of 33% (P = 0.0014) was observed in conceptions attributable to oocytes exposed to cyclophosphamide at the earliest stages of follicle growth. With an extended interval between exposure and mating the malformation rate gradually decreased towards normal values in the 12th week group. This study suggests that the effect of cyclophosphamide on female gametes and subsequently on future reproduction is influenced by the stage of oocyte maturation at the time of exposure. Early fertilization post-chemotherapy can result in a high rate of pregnancy failure and high malformation rate. This should be taken into account when considering the use of oocyte retrieval, IVF and embryo cryopreservation in patients currently undergoing chemotherapy.
Key words: cyclophosphamide/malformation/oocyte/pregnancy/resorption
5 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Rabin Medical Center, Israel.E-mail: meirow{at}md2.huji.ac.il
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury Oncologist, September 1, 2007; 12(9): 1055 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meirow and E. Schiff Appraisal of Chemotherapy Effects on Reproductive Outcome According to Animal Studies and Clinical Data J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 21 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus Lupus, December 1, 2004; 13(12): 887 - 890. [PDF]
|
|
|
|
 |
|
 S. Di Cosimo, A. Alimonti, G. Ferretti, I. Sperduti, P. Carlini, P. Papaldo, A. Fabi, A. Gelibter, M. Ciccarese, D. Giannarelli, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer Ann. Onc., July 1, 2004; 15(7): 1065 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meirow, G. Assad, J. Dor, and J. Rabinovici The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum. Reprod., June 1, 2004; 19(6): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oktay, E. Buyuk, O. Davis, I. Yermakova, L. Veeck, and Z. Rosenwaks Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen Hum. Reprod., January 1, 2003; 18(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsui, Y. Iitsuka, K. Suzuka, K. Yamazawa, K. Seki, and S. Sekiya Outcome of subsequent pregnancy after treatment for persistent gestational trophoblastic tumour Hum. Reprod., February 1, 2002; 17(2): 469 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Effects of Cyclophosphamide on Reproduction in Mice Journal Watch Women's Health, May 1, 2001; 2001(501): 4 - 4. [Full Text]
|
|